ангиотензин II,常规血管压缩剂治疗,以及休克死亡率:一个大型的,多中心的,倾向性得分加权分析
Laurence W Busse1,2,3, Caitlin Ten Lohuis4,5, Han Xu6
1Emory Critical Care Center, Emory Healthcare, Atlanta, GA, USA. laurence.w.busse@emory.edu.
Annals of intensive care
|July 23, 2025
概括
将 ангиотензин II (Ang II) 添加到传统的休克疗法可能会降低死亡率,特别是在需要中等剂量的北上腺素等效 (NE) 剂量的患者中. 需要进一步的研究,但Ang II在特定的NE剂量范围内显示出潜在的益处.
科学领域:
- 关键护理医学 关键护理医学
- 心血管药理学心血管药理学
- 冲击管理的管理.
背景情况:
- ангиотензин II (Ang II) 与常规的休克疗法一起使用.
- 它对患者结果的影响仍然不确定.
- 研究Ang II在不同血管压力支持水平中的作用至关重要.
研究的目的:
- 评估安吉奥素II (Ang II) 使用与休克患者死亡率之间的关联.
- 为了评估这种关联在不同剂量的诺拉上腺素等效 (NE) 治疗中.
主要方法:
- 来自四个医疗中心的811名休克患者的回顾性分析.
- 在接受Ang II加常规治疗和仅接受常规治疗的患者之间比较结果.
- 使用倾向性得分权重 (IPTW) 和多变量逻辑回归进行分析,按NE剂量增加进行分层.
主要成果:
- 整体30天死亡率为56.4%.
- 在未调整和调整的分析中,Ang II使用与30天死亡率的降低有关 (OR 0.65,p=0.025;IPTW OR 0.74,p=0.040).
- 这种生存益处在接受NE剂量在0.4至0.6mcg/kg/min之间的患者中观察到,但在更高剂量 (>0.6mcg/kg/min) 时没有.
结论:
- ангиотензин II (Ang II) 的使用与休克患者的死亡率降低相关.
- 安格II的益处在需要中等背景北上腺素等效 (NE) 剂量 (0.4-0.6mcg/kg/min) 的患者中最明显.
- 研究结果表明,Ang II在特定的血管压缩剂剂量范围内可能是一个有价值的治疗选择,这需要在前性研究中进一步调查.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
891
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
891
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
928
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
928
01:30Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
79
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
79
01:29Heart Failure II: Pathophysiology
45
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
45